IFNL3 and fibrosis: Although this study did not find Week 2 response to be sufficient to select patients in whom reduction of simeprevir plus PR treatment duration to 12 weeks is likely to be effective, several baseline host and viral factors (namely mild fibrosis, IL28B CC genotype and low baseline viral load) were found to be associated with high efficacy of this shortened regimen.